Tech Track 100

Astex Technology changed its name to Astex Therapeutics this year to symbolise the fact that one of its anti-cancer drugs had progressed to clinical trials. Headed by Timothy Haines, it helped to pioneer the use of x-ray crystallography to identify new drugs. The company also collaborates on research with the likes of Astra Zeneca and Aventis, which fund Astex’s research programme and pay royalties. Having raised £51m in venture capital since 2001, the company has boosted its sales 47% a year from £1.4m in 2002 to £3m in 2004, when Astex made a substantial loss.

This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.

Company details
CompanyAstex Therapeutics
ActivityDrug developer
Average 3 year sales growth46.63%
Latest sales £000s3,040

If applicable:

* supplied by company † annualised figure